Petah Tikva, Israel 49100 IGF-I is carried in body fluids by specific high-affinity binding proteins that modulate its metabolic and pro¬ liférative actions (1) (2) (3) (4) (5) . While the precise mechanism by which IGFBPs modulate the interaction of ÍGF-I with its receptor is unclear, the regulation of ÍGFBPs seems crucial to the availability of free IGF-I, its activity and clearance. To date, six IGFBPs have been identified, sequenced and termed IGFBP-1 through (6, 7) . Understanding of the regulation of IGFBP synthesis is incomplete. IGFBP-1 and IGFBP-2 are inversely related to plasma GH and insulin levels (8) (9) (10) , while IGFBP-3, the predominant binding protein in serum, is GH dependent (1, 11) . Administration of ÍGF-I to cell cultures and animal models has been shown to induce an increase in IGFBP-3 (12) (13) (14) (15) . However, it is unclear whether in humans an elevation in IGFBP-3 can be achieved by IGF-I in the absence of GH activity.
Laron-type dwarfism (LTD) is an inherited syndrome characterized by extremely low serum IGF-I levels, despite high levels of biologically active GH and by resistance to exogenous GH (16) (17) (18) . The disease is caused by defects in the GH receptor gene, leading to the absence of functional GH receptors (19, 20 
Materials and methods

Subjects
Six proven LTD patients (two children and four adults) whose pertinent data are given in Table 1 (Figs. 1, 2) , as previously reported (9, 26, 27) . The relative amount of serum fGFBP-3 in LTD children was only 5% of age-matched controls (Fig. 1, left panel) , while mean serum fGFBP-3 in the adult LTDs was 16% of adult control levels (Fig. 2, right (Fig. 2, left panel), fn adult LTDs, the increase in IGFBP-3 was less dramatic and serum levels remained lower than in controls (Fig. 2, right panel) . The increase in IGFBP-3 was a slowly progressive process, and closely paralleled the increase in serum IGF-I. After one week of therapy, fGFBP-3 was only slightly increased in most patients, with a reduction in IGFBP-3 in two patients as pre¬ viously described (27) . The increase in IGFBP-3 was evident in all patients after four weeks of therapy.
ÍGFBP-2 was the most prominent IGFBP in serum of LTD children (Fig. 1) and its levels were 200-380% higher than in controls, while in adult LTD patients IGFBP-2 levels resembled that found in controls (Fig. 3) . Chronic administration of fGF-I provoked a steady rise in serum IGFBP-2 which was more evident in adults whose serum IGFBP-2 levels were relatively lower before therapy (Fig. 3) .
The 30 kDa IGFBP, most probably representing IGFBP-1, was higher in LTD children compared with controls, while in adult LTD patients its level resembled controls (Fig. 3 ). An early consistent rise in serum IGFBP-1 was noted in most LTD patients with chronic IGF-1 treatment (Fig. 3) . This increase was inversely correlated to the decrease in fasting plasma insulin levels seen with IGF-I therapy.
Serum levels of the 24 kDa binding protein, presum¬ ably representing IGFBP-4, were not consistently differ¬ ent from those in controls. Nevertheless, a steady increase was observed in all patients upon exposure to fGF-I therapy (Fig. 3) . It is noteworthy that despite the increase in IGFBP-1 and IGFBP-4 levels during IGF-I therapy they remained a relatively small percentage of components of the total IGFBPs (Fig. 1) . Weeks of IGF-I therapy (9) . Thus the exact role of GH/IGF-I in the regulation of fGFBP-2 is complex and may be modulated by changes in insulin levels (9) . Recently, we have shown that chronic fGF-f therapy led to a striking stimulation of growth in children with Laron dwarfism (31) . Of great interest is the question whether the increase in fGFBP-3 is a prerequisite to the observed growth-promoting effects of fGF-I. The progres¬ sive increase in IGFBP-3 levels alters the pharmacokinetics of exogenous fGF-f and enables the achievement of higher serum IGF-I levels and a slower clearance (32) . Consequently, the prolonged duration of fGF-I in the circulation may allow the manifestation of its full effect on growth promotion, thus leading to the striking catch¬ up growth in LTD children during IGF-I therapy (31) . The GH-independent production of IGFBP-3, which seems essential to permit growth, implies that IGF-I therapy may be more appropriate than GH (28) .
